Capricor Therapeutics (CAPR) Competitors $18.92 +0.46 (+2.49%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CAPR vs. CLSD, LPTX, TNXP, NRBO, PRPH, MLTX, AGIO, VRNA, PTCT, and DYNShould you be buying Capricor Therapeutics stock or one of its competitors? The main competitors of Capricor Therapeutics include Clearside Biomedical (CLSD), Leap Therapeutics (LPTX), Tonix Pharmaceuticals (TNXP), NeuroBo Pharmaceuticals (NRBO), ProPhase Labs (PRPH), MoonLake Immunotherapeutics (MLTX), Agios Pharmaceuticals (AGIO), Verona Pharma (VRNA), PTC Therapeutics (PTCT), and Dyne Therapeutics (DYN). These companies are all part of the "pharmaceutical preparations" industry. Capricor Therapeutics vs. Clearside Biomedical Leap Therapeutics Tonix Pharmaceuticals NeuroBo Pharmaceuticals ProPhase Labs MoonLake Immunotherapeutics Agios Pharmaceuticals Verona Pharma PTC Therapeutics Dyne Therapeutics Capricor Therapeutics (NASDAQ:CAPR) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, risk, earnings, media sentiment, dividends and valuation. Do analysts rate CAPR or CLSD? Capricor Therapeutics presently has a consensus price target of $34.50, suggesting a potential upside of 82.35%. Clearside Biomedical has a consensus price target of $5.33, suggesting a potential upside of 407.94%. Given Clearside Biomedical's higher probable upside, analysts clearly believe Clearside Biomedical is more favorable than Capricor Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Capricor Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Clearside Biomedical 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, CAPR or CLSD? Capricor Therapeutics has a beta of 4, meaning that its stock price is 300% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 2.33, meaning that its stock price is 133% more volatile than the S&P 500. Does the MarketBeat Community favor CAPR or CLSD? Clearside Biomedical received 11 more outperform votes than Capricor Therapeutics when rated by MarketBeat users. Likewise, 67.52% of users gave Clearside Biomedical an outperform vote while only 63.52% of users gave Capricor Therapeutics an outperform vote. CompanyUnderperformOutperformCapricor TherapeuticsOutperform Votes35763.52% Underperform Votes20536.48% Clearside BiomedicalOutperform Votes36867.52% Underperform Votes17732.48% Which has stronger earnings & valuation, CAPR or CLSD? Capricor Therapeutics has higher revenue and earnings than Clearside Biomedical. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Clearside Biomedical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCapricor Therapeutics$25.18M34.17-$22.29M-$1.06-17.85Clearside Biomedical$8.23M9.68-$32.49M-$0.45-2.33 Is CAPR or CLSD more profitable? Capricor Therapeutics has a net margin of -146.86% compared to Clearside Biomedical's net margin of -413.83%. Clearside Biomedical's return on equity of 0.00% beat Capricor Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Capricor Therapeutics-146.86% -112.95% -57.00% Clearside Biomedical -413.83%N/A -92.90% Do institutionals and insiders believe in CAPR or CLSD? 21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 18.8% of Clearside Biomedical shares are held by institutional investors. 12.0% of Capricor Therapeutics shares are held by company insiders. Comparatively, 9.2% of Clearside Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer CAPR or CLSD? In the previous week, Capricor Therapeutics had 12 more articles in the media than Clearside Biomedical. MarketBeat recorded 24 mentions for Capricor Therapeutics and 12 mentions for Clearside Biomedical. Clearside Biomedical's average media sentiment score of 0.65 beat Capricor Therapeutics' score of 0.46 indicating that Clearside Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Capricor Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Clearside Biomedical 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCapricor Therapeutics beats Clearside Biomedical on 9 of the 16 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Capricor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CAPR vs. The Competition Export to ExcelMetricCapricor TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$839.38M$6.48B$5.06B$8.89BDividend YieldN/A8.11%4.97%4.06%P/E Ratio-17.854.8389.0213.30Price / Sales34.17372.991,207.2881.01Price / CashN/A52.2739.1736.03Price / Book12.617.876.085.74Net Income-$22.29M$153.61M$119.07M$225.93M7 Day Performance2.33%-2.00%-1.84%-1.32%1 Month Performance-8.02%-7.47%-3.65%0.60%1 Year Performance547.95%31.80%31.62%26.23% Capricor Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CAPRCapricor Therapeutics3.8223 of 5 stars$18.92+2.5%$34.50+82.3%+537.0%$839.38M$25.18M-17.85N/AAnalyst RevisionCLSDClearside Biomedical3.0244 of 5 stars$1.05+1.9%$5.33+407.9%+8.1%$79.63M$8.23M-2.2930Analyst RevisionLPTXLeap Therapeutics2.3936 of 5 stars$2.59-4.1%$7.50+189.6%+25.1%$69.12M$1.50M0.0040Positive NewsTNXPTonix Pharmaceuticals2.9619 of 5 stars$0.19+18.8%$53.50+28,057.9%-98.8%$22.33M$7.77M0.00103Analyst ForecastGap UpHigh Trading VolumeNRBONeuroBo Pharmaceuticals2.331 of 5 stars$2.40-2.0%$10.00+316.7%-31.1%$21.11MN/A0.008PRPHProPhase Labs3.242 of 5 stars$0.77+1.3%$11.00+1,337.9%-82.8%$18.14M$44.38M0.00130MLTXMoonLake Immunotherapeutics3.2689 of 5 stars$49.82+1.0%$79.00+58.6%+16.8%$3.15BN/A0.002AGIOAgios Pharmaceuticals3.3124 of 5 stars$54.62+0.4%$52.33-4.2%+154.0%$3.10B$32.87M4.81390VRNAVerona Pharma2.5968 of 5 stars$38.85+2.0%$43.83+12.8%+163.7%$3.04B$460,000.000.0030Positive NewsPTCTPTC Therapeutics2.5538 of 5 stars$41.96+6.6%$42.00+0.1%+89.3%$3.04B$937.82M0.001,410Analyst DowngradeDYNDyne Therapeutics3.3831 of 5 stars$29.99+1.0%$51.40+71.4%+181.6%$3.02BN/A0.00100Insider TradeAnalyst Revision Related Companies and Tools Related Companies CLSD Competitors LPTX Competitors TNXP Competitors NRBO Competitors PRPH Competitors MLTX Competitors AGIO Competitors VRNA Competitors PTCT Competitors DYN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CAPR) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
